Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Novartis Files Afinitor for GI and Lung Neuroendocrine Tumors in Japan
September 24, 2015
- Amgen Gets Rights to MTPC’s Dyslipidemia Drug after Dezima Acquisition
September 18, 2015
- Chugai Seeks Cervical Cancer Indication for Avastin
September 18, 2015
- Opdivo Gets Breakthrough Therapy Designation for RCC
September 18, 2015
- 1 in 4 Elderly Japanese on 5 or More Prescribed Meds: Pharmacy Survey
September 17, 2015
- Eli Lilly’s Once-Weekly GLP-1 Hits Japan Market
September 17, 2015
- RaQualia Won’t Rule Out Control by Another Firm, Eyes Black Ink in 2018-2019: CEO
September 16, 2015
- Yervoy Will Be First Choice for BRAF-Negative Malignant Melanoma: Skin Cancer Specialist
September 16, 2015
- Daiichi Sankyo Licenses Thrombus Dissolving Agent from US Firm
September 16, 2015
- MTPC Calls Off Japan PIII Program for Alzheimer’s Treatment
September 16, 2015
- Takeda Joins WIPO Consortium for Neglected Tropical Diseases
September 15, 2015
- Takeda Actos Settlement Expected to Become Effective
September 15, 2015
- Lilly Holds Partnering Event in Japan to Unearth Unique Seeds, R&D Chief Interested in 10-Plus Projects
September 14, 2015
- Takeda, Gencia Join Hands to Develop Novel Mitochondrial Therapeutics
September 14, 2015
- Eisai, Swiss Nonprofit to Jointly Develop Eumycetoma Treatment
September 14, 2015
- Novartis Paid 18.3 Billion Yen to Doctors, Medical Institutions in 2014
September 14, 2015
- Pfizer to Enjoy Monopoly in Asacol Generic Market until December
September 14, 2015
- Fluvoxamine Shows Significant Difference against Placebo for Pediatric Obsessive-Compulsive Disorder in PIII Study: Meiji Seika Pharma
September 14, 2015
- FDA Grants Priority Review Status to Multiple Myeloma Drug Ixazomib: Takeda
September 11, 2015
- Ethical Drug Sales Up 6.5% in July: Crecon Report
September 10, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…